RESEARCH TRIANGLE PARK, N.C., June 5, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that on June 4, 2015, new employee David Angulo, M.D., the company's Chief Medical Officer, was granted an option to purchase 125,000 shares of the company's common stock, at a per share exercise price of $8.65, the closing trading price on June 4, 2015. The stock option was granted pursuant to SCYNEXIS' 2015 Inducement Award Plan, which was adopted by the company's board of directors in March 2015 under Rule 5635(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
About SCYNEXIS, Inc.
SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com.
CONTACT: Media Relations Heather Savelle MacDougall Biomedical Communications Tel: 781-235-3060 firstname.lastname@example.org Investor Relations Jillian Connell The Trout Group LLC Tel: 646.378.2956 email@example.comSource:SCYNEXIS, Inc.